1 2 6 7 TEVRA BRANDS LLC, Case No. 19-cv-04312-BLF
8 Plaintiff, ORDER GRANTING 9 v. ADMINSTRATIVE MOTIONS; DENYING ADMINISTRATIVE 10 BAYER HEALTHCARE LLC, et al., MOTIONS
11 Defendants. [Re: ECF Nos. 422, 427, 428, 430, 449, 453, 12 459]
13 14 Before the court are seven administrative motions filed in connection with the parties’ trial 15 briefs: 16 1. Administrative Motion to Consider Whether Another Party’s Material Should Be 17 Sealed. ECF No. 422. 18 2. Administrative Motion to File Under Seal. ECF No. 427. 19 3. Administrative Motion to Consider Whether Another Party’s Material Should Be 20 Sealed. ECF No. 428. 21 4. Administrative Motion to Consider Whether Another Party’s Material Should Be 22 Sealed. ECF No. 430. 23 5. Administrative Motion to Consider Whether Another Party’s Material Should Be 24 Sealed. ECF No. 449. 25 6. Administrative Motion to Consider Whether Another Party’s Material Should Be 26 Sealed. ECF No. 453. 27 7. Administrative Motion to Consider Whether Another Party’s Material Should Be 1 For the reasons described below, the Court rules as follows: the administrative motions at 2 ECF Nos. 422, 427, 449, and 459 are GRANTED; the administrative motions at ECF No. 428, 3 430, and 453 are DENIED. 5 “Historically, courts have recognized a ‘general right to inspect and copy public records 6 and documents, including judicial records and documents.’” Kamakana v. City & Cty. Of 7 Honolulu, 447 F.3d 1172, 1178 (9th Cir. 2006) (quoting Nixon v. Warner Commc'ns, Inc., 435 8 U.S. 589, 597 & n.7 (1978)). Accordingly, when considering a sealing request, “a ‘strong 9 presumption in favor of access’ is the starting point.” Id. (quoting Foltz v. State Farm Mut. Auto. 10 Ins. Co., 331 F.3d 1122, 1135 (9th Cir. 2003)). Parties seeking to seal judicial records relating to 11 motions that are “more than tangentially related to the underlying cause of action” bear the burden 12 of overcoming the presumption with “compelling reasons” that outweigh the general history of 13 access and the public policies favoring disclosure. Ctr. for Auto Safety v. Chrysler Grp., 809 F.3d 14 1092, 1099 (9th Cir. 2016); Kamakana, 447 F.3d at 1178–79. 15 Records attached to motions that are “not related, or only tangentially related, to the merits 16 of a case,” however, are not subject to the strong presumption of access. Ctr. for Auto Safety, 809 17 F.3d at 1099; see also Kamakana, 447 F.3d at 1179 (“[T]he public has less of a need for access to 18 court records attached only to non-dispositive motions because those documents are often 19 unrelated, or only tangentially related, to the underlying cause of action.”). Parties moving to seal 20 the documents attached to such motions must meet the lower “good cause” standard of Rule 21 26(c). Kamakana, 447 F.3d at 1179 (internal quotations and citations omitted). This standard 22 requires a “particularized showing,” id., that “specific prejudice or harm will result” if the 23 information is disclosed. Phillips ex rel. Estates of Byrd v. Gen. Motors Corp., 307 F.3d 1206, 24 1210–11 (9th Cir. 2002); see Fed. R. Civ. P. 26(c). “Broad allegations of harm, unsubstantiated 25 by specific examples of articulated reasoning” will not suffice. Beckman Indus., Inc. v. Int'l Ins. 26 Co., 966 F.2d 470, 476 (9th Cir. 1992). 27 \\ 2 A. ECF No. 422 3 Bayer filed the Administrative Motion to Consider Whether Another Party’s Material 4 Should Be Sealed on July 15, 2024. ECF No. 422. Tevra submitted a declaration seeking to seal 5 selected portions of certain trial exhibits and deposition transcripts. ECF No. 455. Tevra writes 6 that the information should be sealed because “confidential terms offered to named retailers Tevra 7 targeted, financial information such as profit estimates, projections, and financing decisions, 8 internal communications regarding business strategy and predictions, agreements with named 9 entities, and competitive strategy including Tevra’s comparisons with competitors.” Id. ¶ 3. 10 Tevra argues that the portions are narrowly tailored. Id. ¶ 4. 11 The Court finds that compelling reasons exist to seal the highlighted portions of the 12 document. See Finjan, Inc. v. Proofpoint, Inc., No. 13-CV-05808-HSG, 2016 WL 7911651, at *1 13 (N.D. Cal. Apr. 6, 2016) (finding “technical operation of [defendant's] products” sealable under 14 “compelling reasons” standard); Exeltis USA Inc. v. First Databank, Inc., No. 17-CV-04810-HSG, 15 2020 WL 2838812, at *1 (N.D. Cal. June 1, 2020) (noting that courts have found “confidential 16 business information” in the form of “business strategies” sealable under the compelling reasons 17 standard.). The Court also finds that the request is narrowly tailored. 18 The Court’s ruling is summarized below:
19 ECF or Document Portion(s) to Seal Ruling 20 Exhibit No. Trial Exhibit Entire Exhibit Granted, as it contains terms offered 21 2130 to named retailers as part of Tevra's offer to contract to sell generic 22 imidacloprid topicals. 23 Trial Exhibit Entire Exhibit Granted, as it contains financial 24 2133 information. like profit projections, terms offered to named retailers as 25 part of Tevra's offer to contract to sell generic imidacloprid topicals, 26 and confidential business strategy. 27 Trial Exhibit Entire Exhibit Granted, as it contains internal 1 2319) communications regarding 2 competitive strategy and updates. 3 Trial Exhibit Entire Exhibit Granted, as it contains internal 4 2305) communications regarding competitive strategy and updates. 5 Asimow Decl. 213:13-214:11, 214:18- Granted, as it contains internal 6 Exhibit O 19, 214:22-25; 215:1-13, business strategy and projections (Shaddy Depo) 16-17; 216:1-2, 5-8, 11- regarding possible sales with named 7 12, 15-24; 217:1-5, 19-25; retailers. 218:1 -13, 20-25; 219:1-6. 8 Asimow Decl. 127: 1-19. Granted, as it discusses source of 9 Exhibit P Tevra’s sales projections. (Stichler Depo) 10 Asimow Decl. 41:9-17; 117:1-3,6-8,20- Granted, as it contains Tevra's 11 Exhibit R 25; 118:1-9; 119:19-21, internal financial decisions and (Scharf Depo) 24-25; 154:24; 155:23; figures for money invested. 12 156:8; 159:19-25. Discussion of Tevra's confidential marketing and business strategy, and 13 agreements with named entities. 14 A. ECF No. 427 15 Bayer filed the Administrative Motion to File Under Seal on July 15, 2024. ECF No. 427. 16 Bayer seeks to seal selected portions of its trial brief, writing that the information should be sealed 17 because “portions of the brief contain confidential, highly sensitive information regarding Bayer’s 18 retailer agreements, customers, and marketing strategies.” Id. ¶ 7. Bayer argues that the portions 19 are narrowly tailored. Id. at 2. 20 The Court finds that compelling reasons exist to seal the highlighted portions of the 21 document. See Finjan, Inc. v. Proofpoint, Inc., No. 13-CV-05808-HSG, 2016 WL 7911651, at *1 22 (N.D. Cal. Apr. 6, 2016) (finding “technical operation of [defendant's] products” sealable under 23 “compelling reasons” standard); Exeltis USA Inc. v. First Databank, Inc., No. 17-CV-04810-HSG, 24 2020 WL 2838812, at *1 (N.D. Cal. June 1, 2020) (noting that courts have found “confidential 25 business information” in the form of “business strategies” sealable under the compelling reasons 26 standard.). The Court also finds that the request is narrowly tailored. 27 The Court’s ruling is summarized below: 1 ECF or Document Portion(s) to Seal Ruling 2 Exhibit No. Defendant Highlighted portions at p.
Free access — add to your briefcase to read the full text and ask questions with AI
1 2 6 7 TEVRA BRANDS LLC, Case No. 19-cv-04312-BLF
8 Plaintiff, ORDER GRANTING 9 v. ADMINSTRATIVE MOTIONS; DENYING ADMINISTRATIVE 10 BAYER HEALTHCARE LLC, et al., MOTIONS
11 Defendants. [Re: ECF Nos. 422, 427, 428, 430, 449, 453, 12 459]
13 14 Before the court are seven administrative motions filed in connection with the parties’ trial 15 briefs: 16 1. Administrative Motion to Consider Whether Another Party’s Material Should Be 17 Sealed. ECF No. 422. 18 2. Administrative Motion to File Under Seal. ECF No. 427. 19 3. Administrative Motion to Consider Whether Another Party’s Material Should Be 20 Sealed. ECF No. 428. 21 4. Administrative Motion to Consider Whether Another Party’s Material Should Be 22 Sealed. ECF No. 430. 23 5. Administrative Motion to Consider Whether Another Party’s Material Should Be 24 Sealed. ECF No. 449. 25 6. Administrative Motion to Consider Whether Another Party’s Material Should Be 26 Sealed. ECF No. 453. 27 7. Administrative Motion to Consider Whether Another Party’s Material Should Be 1 For the reasons described below, the Court rules as follows: the administrative motions at 2 ECF Nos. 422, 427, 449, and 459 are GRANTED; the administrative motions at ECF No. 428, 3 430, and 453 are DENIED. 5 “Historically, courts have recognized a ‘general right to inspect and copy public records 6 and documents, including judicial records and documents.’” Kamakana v. City & Cty. Of 7 Honolulu, 447 F.3d 1172, 1178 (9th Cir. 2006) (quoting Nixon v. Warner Commc'ns, Inc., 435 8 U.S. 589, 597 & n.7 (1978)). Accordingly, when considering a sealing request, “a ‘strong 9 presumption in favor of access’ is the starting point.” Id. (quoting Foltz v. State Farm Mut. Auto. 10 Ins. Co., 331 F.3d 1122, 1135 (9th Cir. 2003)). Parties seeking to seal judicial records relating to 11 motions that are “more than tangentially related to the underlying cause of action” bear the burden 12 of overcoming the presumption with “compelling reasons” that outweigh the general history of 13 access and the public policies favoring disclosure. Ctr. for Auto Safety v. Chrysler Grp., 809 F.3d 14 1092, 1099 (9th Cir. 2016); Kamakana, 447 F.3d at 1178–79. 15 Records attached to motions that are “not related, or only tangentially related, to the merits 16 of a case,” however, are not subject to the strong presumption of access. Ctr. for Auto Safety, 809 17 F.3d at 1099; see also Kamakana, 447 F.3d at 1179 (“[T]he public has less of a need for access to 18 court records attached only to non-dispositive motions because those documents are often 19 unrelated, or only tangentially related, to the underlying cause of action.”). Parties moving to seal 20 the documents attached to such motions must meet the lower “good cause” standard of Rule 21 26(c). Kamakana, 447 F.3d at 1179 (internal quotations and citations omitted). This standard 22 requires a “particularized showing,” id., that “specific prejudice or harm will result” if the 23 information is disclosed. Phillips ex rel. Estates of Byrd v. Gen. Motors Corp., 307 F.3d 1206, 24 1210–11 (9th Cir. 2002); see Fed. R. Civ. P. 26(c). “Broad allegations of harm, unsubstantiated 25 by specific examples of articulated reasoning” will not suffice. Beckman Indus., Inc. v. Int'l Ins. 26 Co., 966 F.2d 470, 476 (9th Cir. 1992). 27 \\ 2 A. ECF No. 422 3 Bayer filed the Administrative Motion to Consider Whether Another Party’s Material 4 Should Be Sealed on July 15, 2024. ECF No. 422. Tevra submitted a declaration seeking to seal 5 selected portions of certain trial exhibits and deposition transcripts. ECF No. 455. Tevra writes 6 that the information should be sealed because “confidential terms offered to named retailers Tevra 7 targeted, financial information such as profit estimates, projections, and financing decisions, 8 internal communications regarding business strategy and predictions, agreements with named 9 entities, and competitive strategy including Tevra’s comparisons with competitors.” Id. ¶ 3. 10 Tevra argues that the portions are narrowly tailored. Id. ¶ 4. 11 The Court finds that compelling reasons exist to seal the highlighted portions of the 12 document. See Finjan, Inc. v. Proofpoint, Inc., No. 13-CV-05808-HSG, 2016 WL 7911651, at *1 13 (N.D. Cal. Apr. 6, 2016) (finding “technical operation of [defendant's] products” sealable under 14 “compelling reasons” standard); Exeltis USA Inc. v. First Databank, Inc., No. 17-CV-04810-HSG, 15 2020 WL 2838812, at *1 (N.D. Cal. June 1, 2020) (noting that courts have found “confidential 16 business information” in the form of “business strategies” sealable under the compelling reasons 17 standard.). The Court also finds that the request is narrowly tailored. 18 The Court’s ruling is summarized below:
19 ECF or Document Portion(s) to Seal Ruling 20 Exhibit No. Trial Exhibit Entire Exhibit Granted, as it contains terms offered 21 2130 to named retailers as part of Tevra's offer to contract to sell generic 22 imidacloprid topicals. 23 Trial Exhibit Entire Exhibit Granted, as it contains financial 24 2133 information. like profit projections, terms offered to named retailers as 25 part of Tevra's offer to contract to sell generic imidacloprid topicals, 26 and confidential business strategy. 27 Trial Exhibit Entire Exhibit Granted, as it contains internal 1 2319) communications regarding 2 competitive strategy and updates. 3 Trial Exhibit Entire Exhibit Granted, as it contains internal 4 2305) communications regarding competitive strategy and updates. 5 Asimow Decl. 213:13-214:11, 214:18- Granted, as it contains internal 6 Exhibit O 19, 214:22-25; 215:1-13, business strategy and projections (Shaddy Depo) 16-17; 216:1-2, 5-8, 11- regarding possible sales with named 7 12, 15-24; 217:1-5, 19-25; retailers. 218:1 -13, 20-25; 219:1-6. 8 Asimow Decl. 127: 1-19. Granted, as it discusses source of 9 Exhibit P Tevra’s sales projections. (Stichler Depo) 10 Asimow Decl. 41:9-17; 117:1-3,6-8,20- Granted, as it contains Tevra's 11 Exhibit R 25; 118:1-9; 119:19-21, internal financial decisions and (Scharf Depo) 24-25; 154:24; 155:23; figures for money invested. 12 156:8; 159:19-25. Discussion of Tevra's confidential marketing and business strategy, and 13 agreements with named entities. 14 A. ECF No. 427 15 Bayer filed the Administrative Motion to File Under Seal on July 15, 2024. ECF No. 427. 16 Bayer seeks to seal selected portions of its trial brief, writing that the information should be sealed 17 because “portions of the brief contain confidential, highly sensitive information regarding Bayer’s 18 retailer agreements, customers, and marketing strategies.” Id. ¶ 7. Bayer argues that the portions 19 are narrowly tailored. Id. at 2. 20 The Court finds that compelling reasons exist to seal the highlighted portions of the 21 document. See Finjan, Inc. v. Proofpoint, Inc., No. 13-CV-05808-HSG, 2016 WL 7911651, at *1 22 (N.D. Cal. Apr. 6, 2016) (finding “technical operation of [defendant's] products” sealable under 23 “compelling reasons” standard); Exeltis USA Inc. v. First Databank, Inc., No. 17-CV-04810-HSG, 24 2020 WL 2838812, at *1 (N.D. Cal. June 1, 2020) (noting that courts have found “confidential 25 business information” in the form of “business strategies” sealable under the compelling reasons 26 standard.). The Court also finds that the request is narrowly tailored. 27 The Court’s ruling is summarized below: 1 ECF or Document Portion(s) to Seal Ruling 2 Exhibit No. Defendant Highlighted portions at p. 1, Granted, as it contains confidential 3 Bayer line 5; p.3, line 24; p.4, lines information relating to Bayer’s HealthCare 8-10, 12, 16; p.6, lines 7-8; retailer agreements, customers, 4 LLC’s Trial p.7, line 21; p.10, lines 2, 4, and marketing strategies. See ECF Brief 6-8, 10, 14-15, 19, 21. No. 427-1 ¶¶ 3-4 5 6 A. ECF No. 428 7 Bayer filed the Administrative Motion to Consider Whether Another Party’s Material 8 Should Be Sealed on July 15, 2024. ECF No. 428. Tevra has not submitted a corresponding 9 declaration. As such, the administrative motion is DENIED. 10 A. ECF No. 430 11 Tevra filed the Administrative Motion to Consider Whether Another Party’s Material 12 Should Be Sealed on July 15, 2024. ECF No. 430. Bayer has not submitted a corresponding 13 declaration. As such, the administrative motion is DENIED. 14 A. ECF No. 449 15 Bayer filed the Administrative Motion to Consider Whether Another Party’s Material 16 Should Be Sealed on July 19, 2024. ECF No. 449. Tevra submitted a declaration seeking to seal 17 selected portions of the trial brief. ECF No. 463. Tevra writes that the information should be 18 sealed because “highlighted portions of the Motion include confidential discussions between 19 Tevra, and a named retailer Tevra dealt with.” Id. ¶ 3. Tevra argues that the portions are narrowly 20 tailored. Id. ¶ 4. 21 The Court finds that compelling reasons exist to seal the highlighted portions of the 22 document. See Finjan, Inc. v. Proofpoint, Inc., No. 13-CV-05808-HSG, 2016 WL 7911651, at *1 23 (N.D. Cal. Apr. 6, 2016) (finding “technical operation of [defendant's] products” sealable under 24 “compelling reasons” standard); Exeltis USA Inc. v. First Databank, Inc., No. 17-CV-04810-HSG, 25 2020 WL 2838812, at *1 (N.D. Cal. June 1, 2020) (noting that courts have found “confidential 26 business information” in the form of “business strategies” sealable under the compelling reasons 27 standard.). The Court also finds that the request is narrowly tailored. 1 ECF or Document Portion(s) to Seal Ruling 2 Exhibit No. Bayer HealthCare Highlighted portions at Granted, as it contains highly 3 LLC's Motion in p. l, lines 2-4, 8, 14, 26; confidential information Limine to Admit p.2, lines 1-3, 5-8, 14-16, regarding communications and 4 Adoptive 18-20, 22, 24-25, 27-28; business decisions with named Admissions p.3, lines 1, 11-12, 22. retailers. 5 6 A. ECF No. 453 7 Bayer filed the Administrative Motion to Consider Whether Another Party’s Material 8 Should Be Sealed on July 22, 2024. ECF No. 428. On July 29, 2024, Tevra submitted a 9 declaration stating that it does not seek any redactions. ECF No. 465. As such, the administrative 10 motion is DENIED. 11 A. ECF No. 459 12 Bayer filed the Administrative Motion to Consider Whether Another Party’s Material 13 Should Be Sealed on July 23, 2024. ECF No. 459. Tevra submitted a declaration seeking to seal 14 selected portions of Bayer’s motion to exclude. ECF No. 467. Tevra writes that the information 15 should be sealed because “highlighted portions of the Motion include confidential discussions 16 between Tevra, and a named retailer Tevra dealt with.” Id. ¶ 3. Tevra argues that the portions are 17 narrowly tailored. Id. ¶ 4. 18 The Court finds that compelling reasons exist to seal the highlighted portions of the 19 document. See Finjan, Inc. v. Proofpoint, Inc., No. 13-CV-05808-HSG, 2016 WL 7911651, at *1 20 (N.D. Cal. Apr. 6, 2016) (finding “technical operation of [defendant's] products” sealable under 21 “compelling reasons” standard); Exeltis USA Inc. v. First Databank, Inc., No. 17-CV-04810-HSG, 22 2020 WL 2838812, at *1 (N.D. Cal. June 1, 2020) (noting that courts have found “confidential 23 business information” in the form of “business strategies” sealable under the compelling reasons 24 standard.). The Court also finds that the request is narrowly tailored. 25 The Court’s ruling is summarized below: 26 \\ 27 \\ | ECF or Document Portion(s) to Seal Ruling 2 Exhibit No. Bayer HealthCare Highlighted portions at | Granted, as it contains highly 3 LLC’s Motion to p. 2 line 22-23; p. 3 line | confidential information Exclude Testimony | 12. regarding communications to 4 Regarding Efficacy named retailers regarding 5 and Safety marketing and comparison of Tevra’s product, and the names of 6 those retailers. 7 || I. ORDER 8 For the foregoing reasons, IT IS HEREBY ORDERED that: 9 1. ECF No. 422 is GRANTED. 10 2. ECF No. 427 is GRANTED. 11 3. ECF No. 428 is DENIED. 12 4. ECF No. 430 is DENIED.
5. ECF No. 449 is GRANTED.
14 6. ECF No. 453 is DENIED.
7. ECF No. 459 is GRANTED. 16 All denials are WITHOUT PREJUDICE. Any refiled administrative motion or declaration
= 17 SHALL be filed no later than August 13, 2024. The parties SHALL refile public versions of each
18 filing where the redactions and sealing granted by the Court are narrower than what was redacted 19 in the current public versions by August 20, 2024, unless they are filing a renewed sealing motion 20 || for any document in that filing. 21 22 || Dated: August 6, 2024
BETH LABSON FREEMAN 24 United States District Judge 25 26 27 28